Drug Approval | July 06, 2025
Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
The audit has been concluded with no major observations
The audit has been concluded with no major observations
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The inspection concluded with zero Form 483 observations
Changhua site meets international regulatory standards for global medical applications
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The company received seven observations in the Form-483
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
The company received 1 (One) observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
